Dendreon (DNDN) third-quarter earnings. Will Provenge sales recover?
North American Cystic Fibrosis Conference: Vertex Pharmaceuticals (VRTX) presenting Kalydeco data. Nov. 4-8
American Association for the Study of Liver Disease (AASLD) annual meeting. Key presentations of hepatitis C drug data from Pharmasset (VRUS), Bristol-Myers Squibb (BMY), Vertex Pharmaceuticals, Merck (MRK), Johnson & Johnson (JNJ) and others. Nov. 5-9
American College of Rheumatology (ACR) annual meeting. Nov. 7
Roche (RHHBY) analyst/investor meeting.
American Society of Hematology (ASH) annual meeting research abstracts released: Ariad Pharmaceuticals (ARIA), Celgene (CELG), YM BioSciences (YMI). Nov. 10
Merck analyst/investor meeting. Nov. 11
FDA approval decision for Alimera Sciences (ALIM - Get Report) and pSivida's (PSDV - Get Report) Iluvien for diabetic macular edema. Nov. 12-16
American Heart Association Scientific Sessions: Aastrom Biosciences (ASTM), Amarin (AMRN).
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Nov. 13
FDA approval decision for IntelGenx's (IGXT.OB) CPI-300 anti-depressant. Nov. 16
FDA advisory panel convened to review Salix Pharmaceuticals' (SLXP) Xifaxan for irritable bowel syndrome with diarrhea. Nov. 18
FDA approval decision for Regeneron Pharmaceuticals' (REGN) Eyelea for age-related macular degeneration. Nov. 27
FDA approval decision for Transcept Pharmaceuticals' (TSPT) Intermezzo sleeping pill. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.